FDA Considers Range of Measures to Enhance Safety of High-Risk Excipients
This article was originally published in The Gold Sheet
Executive Summary
FDA eyes all high-risk excipients in response to DEG-tainted glycerin issue.
You may also be interested in...
Revised US FDA Guidance Calls For Testing More Excipients For DEG And EG
Substantial revision of 2007 DEG guidance comes after hundreds of deaths in seven countries inked to diethylene glycol and ethylene glycol adulteration. All containers and lots of certain additional excipients must be tested, and many others should be.
Revised US FDA Guidance Calls For Testing More Excipients For DEG And EG
Substantial revision of 2007 DEG guidance comes after hundreds of deaths in seven countries that were linked to diethylene glycol and ethylene glycol adulteration. All containers and all lots of certain additional excipients must now be tested, and many others should be.
Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.